



Media Release

Martinsried/Munich, Germany, November 3, 2016

MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) Annual Meeting 2016

Oral presentations on proprietary antibody programs MOR208 and MOR202

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced upcoming presentations of data on the Company's proprietary hemato-oncological programs MOR208 and MOR202 at the 58th American Society of Hematology (ASH) Annual Meeting, being held December 3-6, 2016 in San Diego, California/USA.

"We are pleased that updated clinical trial results with our antibodies MOR208 and MOR202 in patients with B-cell malignancies and multiple myeloma, respectively, will be shown at the upcoming ASH conference as oral presentations," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We expect this will further demonstrate the potential of our proprietary development candidates for patients suffering from those hemato-oncological malignancies that have a particularly high unmet medical need."

Abstracts from MorphoSys's proprietary programs accepted for presentation at ASH 2016:

[Single-Agent MOR208 in Relapsed or Refractory \(R-R\) Non-Hodgkin's Lymphoma \(NHL\): Results from Diffuse Large B-Cell Lymphoma \(DLBCL\) and Indolent NHL Subgroups of a Phase IIa Study](#)

The oral presentation will include updated clinical results, in particular with respect to duration of responses, from a phase 2a MOR208 monotherapy trial in adult patients with relapsed/refractory NHL including DLBCL and iNHL.

Abstract #623

Session Name: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Novel Agents

Session Date: Monday, December 5, 2016

Session Time: 7:00am-8:30am (PST) (4:00pm-5:30pm CET)

Presentation Time: 8:00am PST (5:00pm CET)

Room: San Diego Convention Center, Room 6B

[A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma](#)

The oral presentation will include updated safety and efficacy results from the ongoing phase 1/2a MOR202 dose-escalation study in pre-treated multiple myeloma patients. Results will in particular include maturing data from the MOR202 8mg/kg patient cohorts in combination with lenalidomide and pomalidomide as well as first results from the highest dose cohorts of 16mg/kg MOR202 in combination with lenalidomide and pomalidomide.

Abstract #1152

Session Name: 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy

Session Date: Monday, December 5, 2016

Session Time: 4:30pm-6:00pm (PST) (December 6, 2016, 1:30am-3:00am CET)

Presentation Time: 5:45pm (PST) (December 6, 2016, 2:45am CET)

Room: San Diego Convention Center, Hall AB

[Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia \(CLL\) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones](#)

The poster presentation will include safety and efficacy results from the ongoing phase 2 investigator initiated trial (IIT) of MOR208 in combination with lenalidomide or ibrutinib in CLL.

Abstract #4386

Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III

Date: Monday, December 5, 2016

Presentation Time: 6:00pm-8:00pm (PST) (December 6, 2016, 3:00am-5:00am CET)

Location: San Diego Convention Center, Hall GH

In addition to the presentations, all abstracts will be published online in the December 1, 2016 supplemental volume of Blood.

Additional information can be found at www.hematology.org, including the abstracts.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic [pipeline](#) of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit <http://www.morphosys.com>.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated, MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

Jochen Orlowski

Associate Director Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com